1Rasmussen H B, Branner S,Wiberg F C,et al. Crystal structure of human dipeptidyl peptidase 1V/CD26 in complex with a substrate analog[ J]. Nat Struct Biol,2003,10( 1 ) :19.
2Aschner P,Kipnes M S,Lunceford J K,et al. Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [ J 1. Diabetes Care ,2006,29 ( 12 ) :2632.
3Barnett A. DPP - 4 inhibitors and their potential role in the management of type 2 diabetes [ J ]. Int Clin Pract,2006,60 ( 11 ) : 1454.
4Ristic S, Byiers S, Foley J,et al. Improved glycemic control with dipepti- dyl peptidase -4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response[ J]. Diabetes Obes Metab ,2005,7 (6):692.
5Rosenstock J, Aguilar - Salinas C, Klein E,et al. Effect of saxagliptin inonotherapy in treatment- naive patients with type 2 diabetes[ J]. Curr Med Res 0oin.2009,25 (1) :2401.
6DeFronzo R A,Fleck P R,Wilson C A,et al. Efficacy and safety of the dipeptidy[ peptidase - 4 inhibitor alogliptin in patients with type 2 diabe- tes and inadequate glyeemic control: a randomized, double - blind, pla- cebo - controlled study [ J ]. Diabetes Care,2008,31 ( 12 ) :2315.
7Prattey R E, Kipnes M S, Fleck P R,et al. Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor alogliptin in patients with type 2 diabe- tes inadequately controlled by glyburide monotherapy [ J ]. Diabetes Obes Metab,2009,11 ( 2 ) : 167.
8Del Prato S, Barnett A H,Huisman H,et al. Effect of linagliptin mono- therapy on glycaemic control and markers of - celt function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial[ J. Diabetes Obes Metab,2011,13 ( 3 ) :258.
9Forst T, Uhlig - Laske B, Ring A,et al. Linagliptin ( BI 1356 ) , a potent and selective DPP -4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes [ J]. Diabet Med ,2010,27(12) : 1409.
10Pratley R E, McCall T, Fleck P R,et al. Alogliptin use in elderly peo- ple: a pooled analysis from phase 2 and 3 studies [ J]. J Am Geriatr Soc ,2009,57 ( 11 ) :2011.
